Mere months ago, health experts were divided on whether COVID-19 boosters were necessary for the broader public. Then came delta and then came omicron. Now, Israel is moving to become one of the first countries to offer a fourth dose of COVID-19 vaccine to people at least 60 years old and those at high risk…
J&J joins Moderna and Pfizer in researching Omicron variant
Johnson & Johnson (NYSE:JNJ) has announced that it is collaborating with academic institutions internationally to gauge the effectiveness of its COVID-19 vaccine against Omicron and other SARS-CoV-2 variants. In particular, J&J said it is conducting research on blood serum from clinical trial volunteers who have received single or multiple doses of its COVID-19 vaccine. The…